Medindia
Medindia LOGIN REGISTER
Advertisement

Cipher Pharmaceuticals Reports Q4 & FY2017 Results

Wednesday, February 28, 2018 Drug News
Advertisement

(IN THOUSANDS OF U.S. DOLLARS) 

2017

2016

$

$

Income from continuing operations

10,747

4,219

Add back:

Depreciation and amortization

967

1,121

Interest expense, net

5,292

7,723

Income taxes

3,518

1,492

EBITDA

20,524

14,555

Change in fair value of derivative financial instrument

(34)

(1,175)

Loss (gain) from the translation of Canadian cash balances

35

(10)

Loss on debt extinguishment

5,223

-

Impairment of intangible assets

561

-

Share-based compensation

338

1,405

Adjusted EBITDA

26,647

14,775

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close